Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Provencher, P. Hervé, V. Ioos, X. Jais, D. Lebrec, M. Humbert, G. Simonneau, O. Sitbon (Clamart, Clichy, France). Deleterious effects of ß-blockers on exercise capacity and hemodynamics in portopulmonary hypertension. Eur Respir J 2005; 26: Suppl. 49, 3125

Member's Comments

No comment yet.

Related content which might interest you: Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 393-398 Year: 2008 Pulmonary haemodynamics during exercise in patients with pulmonary arterial hypertension Source: Annual Congress 2005 - Exercise testing in pulmonary arterial hypertension Year: 2005 Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Haemodynamics, exercise capacity and clinical events in pulmonary arterial hypertension Source: Eur Respir J 2013; 42: 414-424 Year: 2013 Pathophysiology of exercise limitation in patients with pulmonary arterial hypertension Source: Annual Congress 2005 - Exercise testing in pulmonary arterial hypertension Year: 2005 The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Contrasting cardiovascular responses to exercise in mitochondrial myopathy and pulmonary arterial hypertension Source: International Congress 2016 – Mechanisms of symptoms and exercise limitation in health and disease Year: 2016 Effects of oxygen supplementation during exercise on hemodynamic responses in patients with pulmonary arterial hypertension Source: Virtual Congress 2020 – New insights into evaluation and treatment of respiratory disease Year: 2020 Relationship between exercise desaturation and pulmonary haemodynamics in COPD patients Source: Eur Respir J 2004; 24 : 580-586 Year: 2004 Predictive factors of developing exercise pulmonary arterial hypertension in emphysematous patients with mild hypoxemia at rest Source: Annual Congress 2005 - COPD - pulmonary haemodynamics and gas exchange Year: 2005 Acute effects of oxygen supplementation during exercise in patients with pulmonary arterial hypertension Source: International Congress 2019 – Exercise physiopathology in various respiratory diseases Year: 2019 Acetazolamide and chronic hypoxia: effects on haemorheology and pulmonary haemodynamics Source: Eur Respir J 2012; 40: 1401-1409 Year: 2012 The prevalence of ventilatory limitation at peak exercise in pulmonary arterial hypertension Source: International Congress 2014 – Alterations of exercise and lung function in different diseases Year: 2014 Haemodynamic effects of exercise therapy in stable, optimally treated pulmonary arterial hypertension Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017 Hemodynamic correlates of exercise capacity in patients with pulmonary hypertension Source: Eur Respir J 2005; 26: Suppl. 49, 17s Year: 2005 Long-term bosentan therapy improves exercise capacity and hemodynamics in sarcoidosis-associated pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments Year: 2012 Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals Year: 2006 Cardiac function during exercise in pulmonary arterial hypertension Source: Annual Congress 2005 - Exercise in pulmonary hypertension Year: 2005